Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
7.62
+0.32 (4.38%)
May 14, 2025, 9:47 AM - Market open
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
$108,522
Profits / Employee
-$344,154
Market Cap
348.06M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CAPR News
- 13 hours ago - Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 8 days ago - Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 - GlobeNewsWire
- 8 days ago - US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
- 9 days ago - Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy - GlobeNewsWire
- 7 weeks ago - Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 2 months ago - FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - PRNewsWire